Senior Blood Test Results: Medication Effects to Check

Categories
Articles
Senior Health Lab Interpretation 2026 Update Medication Safety

Many abnormal results in later life reflect medicines, hydration, or timing rather than a new disease. The useful question is whether the pattern fits the prescription list—and whether it is changing.

📖 ~11 minutes 📅
📝 Published: 🩺 Medically Reviewed: ✅ Evidence-Based
⚡ Quick Summary v1.0 —
  1. Potassium above 5.5 mmol/L while taking an ACE inhibitor, ARB, spironolactone, or trimethoprim merits prompt clinician contact; weakness or palpitations raise urgency.
  2. Sodium below 130 mmol/L can cause falls, confusion, and seizures in older adults, particularly with thiazide diuretics, SSRIs, and carbamazepine.
  3. An eGFR fall of up to 30% after starting an ACE inhibitor, ARB, or SGLT2 inhibitor may be an expected haemodynamic effect, but a larger or progressive fall needs review.
  4. Vitamin B12 below 200 pg/mL (148 pmol/L) is commonly linked to metformin or long-term proton-pump inhibitor use and should not be dismissed as ordinary ageing.
  5. ALT or AST above three times the laboratory upper limit after a new medicine calls for same-week clinical assessment, especially with jaundice, dark urine, or nausea.
  6. INR above the prescribed range in a person taking warfarin can follow antibiotics, reduced dietary vitamin K, diarrhoea, or a new interacting medicine.
  7. HbA1c can look falsely low after recent transfusion, blood loss, or haemolysis; glucose readings and fructosamine may be more informative for several weeks.
  8. A medication list, dose, start date, and last dose time often explains a senior blood test better than a single reference-range flag.

How to read a senior blood test before assuming disease

A senior blood test should be read beside the complete medication and supplement list, not in isolation. A new abnormality that begins within 2 to 12 weeks of a dose change is often medication-related, but it still deserves a clinician's interpretation rather than an automatic reassurance.

Senior blood test review showing medicines beside a laboratory sample and kidney panel
Figure 1: Medication timing and laboratory trends are reviewed together before assigning a cause.

As of September 2, 2026, the most useful first step is to write down every prescription, over-the-counter product, herbal remedy, and dose timing. In my clinical work, the missing item is often ibuprofen bought at a supermarket, a magnesium laxative, or a potassium-containing salt substitute—not the prescribed antihypertensive.

Reference intervals describe 95% of a laboratory's comparison population; they are not personal treatment targets. A creatinine value of 1.15 mg/dL may be unremarkable for one older adult and concerning for another whose stable value was 0.75 mg/dL six months earlier; our guide to a blood test for elderly adults explains why frailty and falls change the interpretation.

Kantesti is an AI blood test analyzer that compares reported values with medication-aware patterns and prior results rather than treating every red flag as a diagnosis. Thomas Klein, MD, recommends bringing the original report and medicine boxes to the appointment; brand substitutions and combination tablets are surprisingly easy to overlook.

Expected ageing changes versus medication effects

Ageing alone modestly lowers kidney filtration and albumin production, but it does not explain abrupt electrolyte, liver-enzyme, or blood-count changes. A result that moves quickly after a medicine starts should be treated as a possible adverse effect until proven otherwise.

Senior blood test comparison of stable age-related laboratory change and medication-related change
Figure 2: A gradual baseline shift differs clinically from an abrupt post-medication change.

Estimated GFR commonly declines by roughly 0.8 to 1 mL/min/1.73 m² per year after midlife, although individual variation is wide. An eGFR below 60 for at least 3 months defines chronic kidney disease only when confirmed or accompanied by another marker of kidney damage; a baseline blood test makes later comparisons much safer.

A new MCV above 100 fL is not a normal feature of getting older. Alcohol, folate deficiency, vitamin B12 deficiency, hypothyroidism, liver disease, hydroxyurea, methotrexate, and some anticonvulsants are common explanations, while persistent macrocytosis with falling haemoglobin needs a proper blood-film and clinical review.

The 2023 American Geriatrics Society Beers Criteria specifically flags several medicines that carry disproportionate risks in older people, including long-term proton-pump inhibitors and combinations that affect kidney function or potassium (American Geriatrics Society Beers Criteria Update Expert Panel, 2023). The practical point is simple: age increases vulnerability to an interaction; it does not make the interaction harmless.

Creatinine and eGFR changes with common medicines

NSAIDs, ACE inhibitors, ARBs, diuretics, trimethoprim, and SGLT2 inhibitors can change creatinine or eGFR in predictable but clinically different ways. An eGFR drop greater than 30% from baseline, or a rising creatinine with low urine output, vomiting, or swelling, needs prompt review.

Senior blood test kidney function analysis with medicine packets and renal laboratory sample
Figure 3: Kidney markers must be interpreted alongside medicines, fluids, and recent illness.

ACE inhibitors and ARBs relax the kidney's efferent arteriole, so creatinine can rise after treatment begins. KDIGO 2024 advises investigating an acute creatinine rise of 30% or more after initiation or dose escalation, particularly when dehydration, renal-artery disease, NSAID use, or excess diuresis may coexist (KDIGO, 2024).

The classic high-risk combination is an ACE inhibitor or ARB plus a diuretic plus an NSAID—the so-called triple whammy. A 79-year-old taking ramipril, furosemide, and naproxen after a knee flare can develop a meaningful eGFR decline within days of poor fluid intake; read more about a temporary low eGFR after dehydration.

Kantesti AI interprets kidney results using the direction and rate of change, not creatinine alone; a 0.2 mg/dL rise has a different meaning at baseline 0.6 mg/dL than at 2.4 mg/dL. Our clinical validation approach is designed to flag combinations needing human follow-up, not to advise stopping a prescribed medicine.

Stable kidney function eGFR change under 10% Usually within biological and measurement variation when the person is well hydrated.
Early post-treatment change eGFR fall 10-29% Can occur after ACE inhibitor, ARB, or SGLT2 initiation; review fluids, dose, and repeat plan.
Concerning decline eGFR fall 30% or more Prompt prescriber review is appropriate, especially with NSAIDs, vomiting, or diarrhoea.
Possible acute kidney injury Rapid rise in creatinine plus low urine output Same-day medical assessment is needed.

Sodium and potassium results that medicines can shift

Thiazide diuretics and SSRIs commonly lower sodium, while ACE inhibitors, ARBs, spironolactone, and trimethoprim can raise potassium. Sodium below 125 mmol/L or potassium at or above 6.0 mmol/L generally warrants urgent same-day assessment, even if symptoms are mild.

Senior blood test electrolyte assessment with diuretic tablets and clinical laboratory analyzer
Figure 4: Electrolyte changes can emerge rapidly after diuretic or interacting medication use.

Hyponatraemia is particularly easy to miss because older adults may present with fatigue, unsteadiness, slower thinking, or a fall rather than obvious thirst. A sodium concentration below 130 mmol/L is clinically significant; thiazides can trigger it within the first 2 weeks, although it may also appear months later during an intercurrent illness.

A potassium of 5.6 mmol/L should be rechecked promptly after considering sampling haemolysis, kidney function, diet, and medicines. Potassium at 6.0 mmol/L or higher can affect cardiac conduction, and the risk is greater when the value rises quickly; our electrolyte result guide explains when an ECG becomes part of the next step.

Loop diuretics more often lower potassium and magnesium, whereas spironolactone tends to retain potassium. Do not self-correct with potassium supplements or salt substitutes: in a person with eGFR 35 mL/min/1.73 m², that well-meant step can turn a modest abnormality into an emergency.

Usual sodium range 135-145 mmol/L Interpret with hydration status and glucose concentration.
Mild hyponatraemia 130-134 mmol/L Review medicines and repeat timing; falls or confusion change urgency.
Moderate hyponatraemia 125-129 mmol/L Prompt clinical assessment is appropriate.
Severe hyponatraemia <125 mmol/L Urgent evaluation is needed, especially with confusion, vomiting, or seizures.

Glucose, HbA1c, and diabetes medication monitoring

Insulin and sulfonylureas can cause dangerous low glucose, while steroids often raise glucose within 24 to 48 hours. HbA1c below 6.5% is not automatically desirable in a frail older adult if it comes with recurrent readings below 70 mg/dL (3.9 mmol/L).

Senior blood test review of glucose and HbA1c beside diabetes medicines
Figure 5: Glucose patterns and HbA1c can disagree after medication or blood-cell changes.

A random glucose below 70 mg/dL is hypoglycaemia, but symptoms can begin at higher levels in someone accustomed to chronic hyperglycaemia. Shaking, sweating, confusion, visual change, or a new fall after insulin or gliclazide should prompt immediate glucose checking and prescriber contact rather than waiting for the next routine senior blood test.

Prednisone 20 mg taken in the morning often produces its largest glucose rise after lunch and supper, while fasting glucose may remain deceptively acceptable. HbA1c reflects approximately 8 to 12 weeks of glycaemia but becomes less reliable after transfusion, significant bleeding, haemolysis, erythropoietin treatment, or advanced kidney disease; see our explanation of when HbA1c can mislead.

SGLT2 inhibitors may produce a small initial eGFR dip while offering long-term kidney and cardiovascular benefit in appropriate patients. A post-SGLT2 eGFR change is therefore interpreted with volume status, ketones when unwell, and the magnitude of decline—not with reflex discontinuation.

B12, folate, and anaemia risks from long-term medicines

Metformin, proton-pump inhibitors, H2 blockers, methotrexate, trimethoprim, and anticonvulsants can alter B12, folate, and blood-cell indices. A B12 level below 200 pg/mL or 148 pmol/L should be evaluated, especially with numb feet, memory change, sore tongue, or MCV above 100 fL.

Senior blood test showing B12 and red cell index review with long-term medication use
Figure 6: Medication-related nutrient depletion may appear first as subtle blood-count changes.

Metformin-associated B12 deficiency becomes more likely with higher dose and longer duration, particularly above 1,500 mg daily for several years. Serum B12 between 200 and 300 pg/mL is a grey zone; methylmalonic acid and homocysteine can help, although kidney impairment can elevate methylmalonic acid independently.

Long-term acid suppression can reduce release of food-bound B12 in the stomach, but not every low-normal value requires injections. A short, practical next step is to check symptoms, full blood count, B12, folate, and possibly MMA before treating; our article on PPI medication monitoring covers the broader pattern.

Iron deficiency in an older adult should not be attributed to acid suppression alone. Ferritin below 30 ng/mL strongly supports depleted iron stores in most uncomplicated settings, whereas a normal ferritin can mask deficiency during inflammation; use a full iron studies guide rather than serum iron alone.

Calcium, magnesium, and bone-treatment safety labs

Calcium supplements, vitamin D, thiazides, antacids, bisphosphonates, denosumab, and PPIs can shift calcium, magnesium, or phosphate. Corrected calcium above 12.0 mg/dL (3.0 mmol/L) or symptomatic low calcium after denosumab requires urgent clinician review.

Senior blood test calcium and magnesium monitoring with supplements and bone-treatment medication
Figure 7: Calcium and magnesium results help identify medication-related mineral imbalance.

Calcium must be read with albumin because low albumin lowers total calcium without necessarily reducing biologically active ionised calcium. A persistently high calcium result should be repeated and paired with parathyroid hormone, kidney function, and a careful list of calcium carbonate chews, vitamin D, and thiazide medicines.

Proton-pump inhibitors can lower magnesium after prolonged use, sometimes after more than 12 months. Magnesium below 1.2 mg/dL (0.5 mmol/L) can contribute to tremor, cramps, low potassium, and arrhythmia; our review of medicine-related low magnesium describes the combination that clinicians watch for.

Denosumab can cause clinically relevant hypocalcaemia, particularly in advanced chronic kidney disease. Tingling around the mouth, hand spasms, confusion, or new muscle twitching after an injection are not symptoms to manage with an internet dose calculation; contact the treating service promptly.

Liver enzymes, bilirubin, and medication effects

Statins, amiodarone, antibiotics, antifungals, paracetamol overdose, anticonvulsants, and supplements can raise liver tests, but the pattern matters more than one enzyme. ALT or AST more than three times the upper limit of normal, or any new jaundice with dark urine, needs prompt assessment.

Senior blood test liver panel interpretation with medication review and enzyme analyzer
Figure 8: The distribution of liver-test changes points toward different medication mechanisms.

An isolated mild ALT rise below twice the upper limit is common and often resolves, but it should be checked against alcohol intake, fatty liver risk, viral exposure, exercise, and medicine timing. GGT is sensitive but nonspecific; a raised GGT with normal bilirubin may reflect enzyme induction, while bilirubin elevation changes the urgency.

Statin-related aminotransferase elevations are usually mild and transient, and true serious liver injury is rare. The 2018 AHA/ACC cholesterol guideline supports continued statin use with clinical judgement rather than routine discontinuation for every small enzyme rise (Grundy et al., 2019); our borderline ALT guide details a sensible repeat strategy.

Kantesti is an AI lab test interpretation service that reads ALT, ALP, GGT, bilirubin, and albumin as a pattern and records the potential medication contribution. Thomas Klein, MD, still advises urgent in-person review for yellow eyes, pale stools, confusion, severe abdominal pain, or dark urine—an AI explanation cannot exclude acute liver injury.

Warfarin, anticoagulants, and blood-count monitoring

Warfarin requires INR monitoring because antibiotics, antifungals, amiodarone, diarrhoea, and reduced vitamin K intake can raise its effect. An INR above 5.0 without major bleeding generally needs same-day anticoagulation advice, while any significant bleeding or head injury is urgent.

Senior blood test INR and full blood count review with anticoagulant medication
Figure 9: Anticoagulant safety depends on INR trends, interactions, and anaemia clues.

INR targets are usually 2.0 to 3.0 for atrial fibrillation and many venous-clot indications, although mechanical valve targets differ. A stable warfarin dose does not guarantee a stable INR: illness and a 7-day antibiotic prescription may alter it substantially; see why antibiotics can raise INR.

Direct oral anticoagulants such as apixaban do not use INR for dose monitoring, but kidney function, haemoglobin, platelets, and drug interactions still matter. A haemoglobin fall of 2 g/dL or more from a recent stable result should trigger a search for bleeding, haemolysis, dilution, and other causes rather than being labelled as routine anaemia.

Platelets below 50 × 10⁹/L materially increase bleeding concern in people using anticoagulants, but a falsely low count from EDTA platelet clumping can occur. A repeat in a citrate tube or a film review can prevent an unnecessary medication change; our platelet clumping explainer shows the laboratory logic.

Statins, lipids, CK, and muscle symptoms

Statins lower LDL cholesterol but can occasionally raise ALT or creatine kinase (CK); new severe muscle pain, weakness, or dark urine needs urgent assessment. CK above 10 times the laboratory upper limit is a common threshold for stopping the drug while clinicians assess possible muscle injury.

Senior blood test review of cholesterol, creatine kinase and statin medication safety
Figure 10: Muscle symptoms and CK results guide safe statin follow-up decisions.

LDL reduction is usually the intended treatment effect, not a laboratory problem. The 2018 AHA/ACC guideline identifies adults aged over 75 as a group where statin continuation or initiation should be individualised around cardiovascular risk, function, preferences, interactions, and expected benefit (Grundy et al., 2019).

A normal CK does not rule out statin-associated muscle symptoms, and a raised CK can follow heavy activity, falls, injections, or hypothyroidism. CK above 1,000 IU/L deserves prompt medical review in most settings, particularly with reduced urine output or dark urine; our high CK warning guide gives practical red flags.

Do not stop a statin solely because total cholesterol now looks low. The meaningful question is whether LDL, ApoB, triglycerides, liver tests, symptoms, and competing risks support the current dose; silent LDL risk is discussed in our high LDL overview.

Thyroid tests when levothyroxine or biotin is involved

Levothyroxine dose changes should usually be assessed with TSH after about 6 to 8 weeks, not after a few days. Biotin supplements can falsely lower TSH and falsely raise free T4 in some immunoassays, creating a misleading hyperthyroid-looking pattern.

Senior blood test thyroid panel review with levothyroxine tablets and assay equipment
Figure 11: Thyroid results depend on dose consistency, timing, and assay interference.

For primary hypothyroidism, TSH is generally the main dose-monitoring test, though targets should be individualised in older adults because overtreatment increases risks of atrial fibrillation and bone loss. A suppressed TSH below 0.1 mIU/L on levothyroxine deserves a prescriber review, particularly if there are palpitations, tremor, weight loss, or falls.

Taking levothyroxine inconsistently, with calcium or iron, or shortly before the sample can complicate interpretation. Calcium carbonate and ferrous sulphate should usually be separated from levothyroxine by at least 4 hours; after a levothyroxine brand switch, a TSH recheck at 6 to 8 weeks is sensible.

Biotin doses of 5 to 10 mg daily, marketed for hair and nails, are much higher than dietary intake and may interfere with susceptible assays. Ask the laboratory or prescriber whether pausing biotin for 48 to 72 hours is appropriate before retesting; never pause thyroid medicine without specific advice.

CBC and liver monitoring for immunosuppressive medicines

Methotrexate, azathioprine, sulfasalazine, biologics, and some anticonvulsants require regular CBC, liver, and kidney monitoring because they can suppress marrow or affect organs before symptoms appear. An absolute neutrophil count below 1.0 × 10⁹/L or platelets below 100 × 10⁹/L needs timely prescriber contact.

Senior blood test full blood count monitoring for immune-modifying medication safety
Figure 12: Full blood count trends can identify medicine toxicity before symptoms become obvious.

The absolute neutrophil count, not the percentage alone, determines infection risk. ANC below 1.5 × 10⁹/L is neutropenia, and below 0.5 × 10⁹/L carries substantially higher risk; fever of 38.0°C or more with severe neutropenia is a same-day emergency.

Methotrexate toxicity becomes more likely with reduced kidney function, dosing errors, trimethoprim, dehydration, and low folate. Mouth ulcers, bruising, new breathlessness, or diarrhoea paired with falling white cells or platelets should be treated as a medication-safety signal, not simply a flare of the underlying condition.

Kantesti is an AI-powered blood test analysis tool that can place CBC, transaminase, eGFR, and prior values on one medication-monitoring timeline. Its interpretation supports—but cannot replace—the specialty team's protocol; our medical advisory board provides clinical oversight of those safety principles.

Senior blood test results that should prompt urgent review

Certain results need action based on the value and symptoms, not on whether the laboratory flag says “high” or “low.” Potassium at or above 6.0 mmol/L, sodium below 125 mmol/L, glucose below 54 mg/dL, and rapidly falling haemoglobin merit urgent assessment.

Senior blood test urgent review pathway with critical electrolyte and blood-count results
Figure 13: A few laboratory patterns require same-day assessment rather than a routine repeat.

Seek emergency help for chest pain, fainting, new one-sided weakness, severe shortness of breath, seizures, black stools, vomiting blood, confusion, or severe dehydration—regardless of the exact number on the report. A laboratory result alone cannot safely triage symptoms, but it can raise the threshold for concern.

A potassium sample can be falsely high from haemolysis or difficult collection, yet this should never be assumed when the result is 6.0 mmol/L or higher. The usual response is an urgent repeat sample and ECG, especially in people with kidney disease or potassium-retaining medicines; see our guide to slightly elevated potassium.

A haemoglobin below 8 g/dL is often clinically significant in older adults, but the correct response depends on baseline, symptoms, cardiac disease, and rate of fall. A drop after hospital discharge may reflect fluids, blood loss, recovery, or marrow suppression; comparing visits is more informative than reacting to one metabolic panel result.

How to prepare for a medication-monitoring follow-up

A good follow-up plan states which result will be repeated, when it will be repeated, and which symptoms override the wait. For many stable medicine changes, a repeat panel in 1 to 2 weeks is appropriate; kidney, potassium, and sodium changes may need earlier testing.

Senior blood test follow-up planning with medication calendar and sequential laboratory samples
Figure 14: A structured timeline makes medication-related laboratory changes easier to interpret.

Record the sampling date and time, fasting status, recent illness, hydration, exercise, alcohol, supplements, and the time of the last dose. This small diary helps distinguish a true result change from ordinary variation; our lab trend analysis guide explains why two values are often more useful than one.

Do not stop anticoagulants, steroids, seizure medicines, insulin, thyroid hormone, or blood-pressure medicines on the basis of a report alone unless an emergency clinician tells you to do so. Abrupt cessation can be more dangerous than the lab abnormality, and a prescriber may instead adjust dose, remove an interaction, or arrange a redraw.

Kantesti AI helps users organise medication monitoring labs across visits, including uploaded PDF reports and photos, but the treating clinician decides diagnosis and treatment. For an explanation of how our methods handle source checks and uncertainty, see the AI technology guide.

Five questions to ask after older adult lab results change

The best questions after older adult lab results change are specific: what changed, which medicine could explain it, what must be repeated, and what symptoms need action? Asking for the prior value and the expected time course often turns a worrying flag into a clear plan.

Ask: “Is this a real change from my baseline, or within expected variation?” For creatinine, haemoglobin, and sodium, the rate of change may matter more than crossing a reference boundary; a side-by-side lab comparison can make the trajectory visible.

Ask: “Could any prescription, supplement, food product, or recent illness be contributing?” A useful medication review includes eye drops, topical medicines, herbal products, and as-needed pain relievers because these are frequently absent from electronic medication lists.

Finally ask: “What number or symptom means I should call today?” Kantesti, an organisation focused on privacy-aware laboratory interpretation, encourages users to share the full report rather than isolated numbers; learn about our clinical team and remit on the About Us page. Most patients find that a written repeat date and red-flag list reduces both missed harm and unnecessary panic.

Frequently Asked Questions

What blood tests should seniors have checked when taking several medicines?

Older adults taking several medicines commonly need a full blood count, creatinine with eGFR, sodium, potassium, liver tests, glucose or HbA1c, and targeted nutrient tests such as B12 or magnesium. The correct panel depends on the drug: ACE inhibitors and diuretics often require kidney function and potassium monitoring, while metformin may justify B12 testing. A sodium below 130 mmol/L or potassium above 5.5 mmol/L should prompt timely clinician contact. The prescriber should set the interval, because a new dose may need testing within 1 to 2 weeks while a stable long-term regimen may not.

Can medications cause low sodium in elderly people?

Yes. Thiazide diuretics, SSRIs, carbamazepine, desmopressin, and some antipsychotics can cause or worsen low sodium in older adults. Sodium below 135 mmol/L is hyponatraemia, and levels below 130 mmol/L can contribute to falls, confusion, nausea, and unsteadiness. Sodium below 125 mmol/L requires urgent medical assessment, especially when neurological symptoms are present. Older adults should not increase salt or stop a prescribed medicine without clinician advice because the cause and safe correction rate matter.

How much creatinine rise is acceptable after starting an ACE inhibitor?

A creatinine rise corresponding to an eGFR fall of less than 30% can occur after starting or increasing an ACE inhibitor or ARB because these medicines change pressure within the kidney filter. KDIGO 2024 recommends investigating a creatinine increase of 30% or more, especially when dehydration, NSAID use, renal-artery disease, or high diuretic doses are possible. The result should usually be compared with a pre-treatment baseline within 1 to 2 weeks of the medication change. Reduced urine output, swelling, dizziness, vomiting, or high potassium makes the review more urgent.

Do statins raise liver enzymes in older adults?

Statins can cause mild ALT or AST elevations, but serious medication-related liver injury is uncommon. ALT or AST values more than three times the laboratory upper limit, particularly with jaundice, dark urine, severe nausea, or elevated bilirubin, need prompt clinical assessment. A small isolated enzyme increase does not automatically mean a statin should be stopped, because fatty liver, alcohol, viral illness, exercise, and other medicines can also contribute. Liver results should be interpreted with symptoms, bilirubin, ALP, GGT, and the treatment benefit.

Can metformin cause low vitamin B12 on a blood test?

Metformin can reduce vitamin B12 absorption, particularly with long-term use and doses above about 1,500 mg daily. A B12 level below 200 pg/mL, equivalent to 148 pmol/L, supports deficiency in many laboratories; values from 200 to 300 pg/mL may need methylmalonic acid or other clinical assessment. Tingling, impaired balance, cognitive symptoms, sore tongue, anaemia, or MCV above 100 fL make follow-up more pressing. Treatment can often correct the deficiency without abandoning metformin, but the plan should be tailored by the prescriber.

When should an older adult seek urgent help for abnormal blood test results?

Older adults should seek urgent help for potassium at or above 6.0 mmol/L, sodium below 125 mmol/L, glucose below 54 mg/dL or 3.0 mmol/L, rapidly falling haemoglobin, or any result accompanied by severe symptoms. Emergency symptoms include chest pain, fainting, severe breathlessness, seizures, confusion, black stools, vomiting blood, or markedly reduced urine output. A result may occasionally need confirmation because of sample error, but urgent review should not be delayed when the value is critical or symptoms are present. The laboratory, prescribing clinic, urgent care service, or emergency department can advise the safest immediate route.

Get AI-Powered Blood Test Analysis Today

Join over 2 million users worldwide who trust Kantesti for instant, accurate lab test analysis. Upload your blood test results and receive comprehensive interpretation of 15,000+ biomarkers in seconds.

📚 Referenced Research Publications

1

Klein, T., Mitchell, S., & Weber, H. (2026). Women's Health Guide: Ovulation, Menopause & Hormonal Symptoms. Kantesti AI Medical Research.

2

Klein, T., Mitchell, S., & Weber, H. (2026). Multilingual AI Assisted Clinical Decision Support for Early Hantavirus Triage: Design, Engineering Validation, and Real-World Deployment Across 50,000 Interpreted Blood Test Reports. Kantesti AI Medical Research.

📖 External Medical References

3

KDIGO CKD Work Group (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International.

4

American Geriatrics Society Beers Criteria Update Expert Panel (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society.

5

Grundy SM et al. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation.

2M+Tests Analyzed
127+Countries
75+Languages

⚕️ Medical Disclaimer

E-E-A-T Trust Signals

Experience

Physician-led clinical review of lab interpretation workflows.

📋

Expertise

Laboratory medicine focus on how biomarkers behave in clinical context.

👤

Authoritativeness

Written by Dr. Thomas Klein with review by Dr. Sarah Mitchell and Prof. Dr. Hans Weber.

🛡️

Trustworthiness

Evidence-based interpretation with clear follow-up pathways to reduce alarm.

🏢 Kantesti LTD Registered in England & Wales · Company No. 17090423 London, United Kingdom · kantesti.net
blank
By Prof. Dr. Thomas Klein

Dr. Thomas Klein is a board-certified clinical hematologist serving as Chief Medical Officer at Kantesti AI. With over 15 years of experience in laboratory medicine and a strong interest in AI-supported interpretation of blood test results, he works to connect new technology with everyday clinical practice. His areas of interest include biomarker analysis, clinical decision support research and population-specific reference range optimization. As CMO, he contributes clinical input to the platform's internal benchmarking and provides clinical oversight for the medical quality of Kantesti's educational reports.

Leave a Reply

Your email address will not be published. Required fields are marked *